47045-TJK-C-UNDP-1 The Global Fund to Fight AIDS, Tuberculosis and Malaria <narrative>Strengthening Supportive Environment and Scaling up Prevention, Treatment and Care to reduce the burden of HIV and TB in the Republic of Tajikistan - Tajikistan (01-Jan-2021-31-Dec-2023)</narrative> Tajikistan, TB/HIV, United Nations Development Programme Goal: To reduce the burden of HIV and TB in Tajikistan. Objectives: To ensure effective HIV response measures among most at risk populations, - including prevention, early HIV diagnostics and immediate treatment initiation, - to reach 90-90-90 HIV care targets; To scale up access for early and quality TB, DR-TB and LTBI diagnosis, treatment and care; To ensure integrated care for people affected both by TB and HIV disease; To strengthen national public heath response to ensure universal, patient-centered, efficient, human rights and gender sensitive approach to HIV, TB and integrated TB/HIV services. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Olga Avdeeva Fund Portfolio Manager +41 58 791 1700 olga.avdeeva@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Tajikistan HIV Tuberculosis Multicomponent, RSSH Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases Achieve universal health coverage HIV -> Differentiated HIV Testing Services -> Community-based testing HIV -> Differentiated HIV Testing Services -> Facility-based testing HIV -> Prevention -> Behavior change interventions HIV -> Prevention -> Condom and lubricant programming HIV -> Prevention -> Needle and syringe programs HIV -> Prevention -> Opioid substitution therapy and other medically assisted drug dependence treatment HIV -> Reducing human rights-related barriers to HIV/TB services -> Stigma and discrimination reduction (HIV/TB) HIV -> Treatment, care and support -> Differentiated ART service delivery and HIV care Multicomponent -> Program management -> Grant management RSSH -> RSSH: Health management information systems and M&E -> Program and data quality RSSH -> RSSH: Health management information systems and M&E -> Routine reporting RSSH -> RSSH: Health management information systems and M&E -> Surveys RSSH -> RSSH: Health products management systems -> Procurement capacity RSSH -> RSSH: Human resources for health, including community health workers -> Community health workers: Education and production RSSH -> RSSH: Human resources for health, including community health workers -> Education and production of new health workers (excluding community health workers) Tuberculosis -> MDR-TB -> Case detection and diagnosis (MDR-TB) Tuberculosis -> MDR-TB -> Treatment (MDR-TB) 3259597.37 13805241.49 13494169.75 3080399.19 16843513.01 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 8745562.81 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 50000.00 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -8097950.20 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 13766048.20 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1054452.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 4282979.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2257140.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 197114.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -50000.00 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 100000.00 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 50000.00 Global Fund disbursement to TJK-C-UNDPP01 (Other 3rd Party). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 10711572.38 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -5974363.20 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3201090.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 237011.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -50000.00 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 680127.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 108185.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5068029.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 95643.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5596313.34 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -1321487.38 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1310393.34 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 100000.00 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2619067.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 468608.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 500000.00 Global Fund disbursement to TJK-C-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 100000.00 Global Fund disbursement to TJK-C-UNDPP01 (Other 3rd Party). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -39690.23 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 39690.23 Funds returned to the Global Fund from TJK-C-UNDPP01 (Other 3rd Party). United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria -519217.00 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 519217.00 Funds returned to the Global Fund from TJK-C-UNDPP01 (Other 3rd Party). United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria -698245.00 Global Fund commitment to TJK-C-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3259597.39 Expenditure reported by United Nations Development Programme for TJK-C-UNDPP01, Jan 2021 to Dec 2021. United Nations Development Programme 12644140.86 Expenditure reported by United Nations Development Programme for TJK-C-UNDPP01, Jan 2022 to Dec 2022. United Nations Development Programme 11727840.99 Expenditure reported by United Nations Development Programme for TJK-C-UNDPP01, Jan 2023 to Dec 2023. United Nations Development Programme 2742311.92 Expenditure reported by United Nations Development Programme for TJK-C-UNDPP01, Jan 2024 to Jun 2024. United Nations Development Programme 99372.43 Expenditure reported by United Nations Development Programme for TJK-C-UNDPP01, Jul 2024 to Mar 2025. United Nations Development Programme <narrative>Grant page on the data explorer of the Global Fund.</narrative> An overview of a grant over its lifetime. <narrative>Grant terms and conditions.</narrative> General terms and conditions which apply to Global Fund grants. <narrative>2020 - Funding Request - Window 1 - TB/HIV - Tajikistan - English</narrative> Funding Request of funding request FR915-TJK-C. <narrative>Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative> Geographic coverage: National, 100% of national program target. <narrative>Percentage of men who have sex with men that have received an HIV test during the reporting period and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of men who have sex with men that have received an HIV test during the reporting period and know their results</narrative> Geographic coverage: National, 100% of national program target. Numerator: 4634; Denominator: 13400. Numerator: 5678; Denominator: 13400. Numerator: 4398; Denominator: 13400. Numerator: 6075; Denominator: 13400. Numerator: 5199; Denominator: 13400. Numerator: 6501; Denominator: 13400. Numerator: 5760; Denominator: 13400. <narrative>Percentage of people who inject drugs that have received an HIV test during the reporting period and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of people who inject drugs that have received an HIV test during the reporting period and know their results</narrative> Geographic coverage: National, 100% of national program target. Numerator: 9440; Denominator: 22200. Numerator: 12540; Denominator: 22200. Numerator: 11159; Denominator: 22200. Numerator: 12915; Denominator: 22200. Numerator: 12233; Denominator: 22200. Numerator: 13746; Denominator: 22200. Numerator: 11277; Denominator: 22200. <narrative>Percentage of sex workers that have received an HIV test during the reporting period and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of sex workers that have received an HIV test during the reporting period and know their results</narrative> Geographic coverage: National, 100% of national program target. Numerator: 7413; Denominator: 17600. Numerator: 8686; Denominator: 17600. Numerator: 7108; Denominator: 17600. Numerator: 9554; Denominator: 17600. Numerator: 8603; Denominator: 17600. Numerator: 10510; Denominator: 17600. Numerator: 9529; Denominator: 17600. <narrative>Number of TB cases with RR-TB and/or MDR-TB notified</narrative> Module: MDR-TB. <narrative>Number of TB cases with RR-TB and/or MDR-TB notified</narrative> Geographic coverage: National, 100% of national program target. <narrative>Number of cases with RR-TB and/or MDR-TB that began second-line treatment</narrative> Module: MDR-TB. <narrative>Number of cases with RR-TB and/or MDR-TB that began second-line treatment</narrative> Geographic coverage: National, 100% of national program target. <narrative>Number of people in prisons and other closed settings reached with HIV prevention programs</narrative> Module: Prevention. <narrative>Number of people in prisons and other closed settings reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. <narrative>Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months</narrative> Module: Prevention. <narrative>Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months</narrative> Geographic coverage: National, 100% of national program target. Numerator: 62; Denominator: 109. Numerator: 148; Denominator: 211. Numerator: 76; Denominator: 122. Numerator: 188; Denominator: 250. Numerator: 98; Denominator: 174. Numerator: 200; Denominator: 250. Numerator: 69; Denominator: 116. <narrative>Percentage of men who have sex with men reached with HIV prevention programs</narrative> Module: Prevention. <narrative>Percentage of men who have sex with men reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. Numerator: 6682; Denominator: 13400. Numerator: 7097; Denominator: 13400. Numerator: 7700; Denominator: 13400. Numerator: 7594; Denominator: 13400. Numerator: 7036; Denominator: 13400. Numerator: 8126; Denominator: 13400. Numerator: 7105; Denominator: 13400. <narrative>Percentage of people who inject drugs reached with HIV prevention programs</narrative> Module: Prevention. <narrative>Percentage of people who inject drugs reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. Numerator: 13653; Denominator: 22200. Numerator: 15674; Denominator: 22200. Numerator: 13258; Denominator: 22200. Numerator: 16144; Denominator: 22200. Numerator: 14644; Denominator: 22200. Numerator: 17183; Denominator: 22200. Numerator: 13052; Denominator: 22200. <narrative>Percentage of sex workers reached with HIV prevention programs</narrative> Module: Prevention. <narrative>Percentage of sex workers reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. Numerator: 10601; Denominator: 17600. Numerator: 10857; Denominator: 17600. Numerator: 10075; Denominator: 17600. Numerator: 11943; Denominator: 17600. Numerator: 12087; Denominator: 17600. Numerator: 13137; Denominator: 17600. Numerator: 11813; Denominator: 17600. <narrative>Number of notified cases of all forms of TB (i.e. bacteriologically confirmed + clinically diagnosed), new and relapse cases</narrative> Module: TB/HIV. <narrative>Number of notified cases of all forms of TB (i.e. bacteriologically confirmed + clinically diagnosed), new and relapse cases</narrative> Geographic coverage: National, 100% of national program target. <narrative>Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative> Module: Treatment, care and support. <narrative>Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative> Geographic coverage: National, 100% of national program target. Numerator: 45; Denominator: 48. Numerator: 115; Denominator: 122. Numerator: 115; Denominator: 115. Numerator: 133; Denominator: 133. <narrative>Percentage of people on ART among all people living with HIV at the end of the reporting period</narrative> Module: Treatment, care and support. <narrative>Percentage of people on ART among all people living with HIV at the end of the reporting period</narrative> Geographic coverage: National, 100% of national program target. Numerator: 7086; Denominator: 14000. Numerator: 9305; Denominator: 14000. Numerator: 8740; Denominator: 14000. Numerator: 10305; Denominator: 14000. Numerator: 9535; Denominator: 14000. Numerator: 11305; Denominator: 14000. Numerator: 10472; Denominator: 14000. 47045-TJK-C-UNDP-2 The Global Fund to Fight AIDS, Tuberculosis and Malaria <narrative>Ending HIV and tuberculosis (“TB”) epidemics through evidence-based interventions and innovative approaches with a focus on key and vulnerable populations - Tajikistan (01-Jan-2024-31-Dec-2026)</narrative> Tajikistan, TB/HIV, United Nations Development Programme Goals: To support Tajikistan public health system by ensuring HIV prevention, timely detection, access to ART, addressing related human rights barriers, as well as providing quality HIV care and support with the focus on key and vulnerable populations; To decrease the burden of tuberculosis and its impact over the general social and economic development in the country, by ensuring universal access to timely and quality diagnosis and treatment of all forms of TB, including latent TB, which will decrease illness and deaths and prevent further development of drug resistance. Objectives: To ensure effective HIV response measures among most at risk populations, - including prevention, early HIV diagnostics and immediate treatment initiation, - to reach 95-95-95 HIV care targets; To reach the pre-pandemic level of access to early and quality DR-TB diagnostics and treatment and scale up integrated people-centered model of TB care; To dramatically scale up efforts on TB/DR-TB prevention, including universal access to TB preventive treatment; To ensure integrated care for people affected both by TB and HIV disease; To strengthen national public heath response to ensure universal, people-centered, efficient, human rights and gender-responsive approach to HIV, TB and integrated TB/HIV services. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Olga Avdeeva Fund Portfolio Manager +41 58 791 1700 olga.avdeeva@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Tajikistan HIV Tuberculosis Multicomponent, RSSH Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases Achieve universal health coverage HIV -> Differentiated HIV Testing Services -> Community-based testing for KP programs HIV -> Differentiated HIV Testing Services -> Facility-based testing for key population (KP) programs HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Condom and lubricant programming for MSM HIV -> Prevention package for people in prisons and other closed settings -> Harm reduction interventions for drug use for prisoners HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Condom and lubricant programming for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Needle and syringe programs for PWID HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Opioid substitution therapy and other medically assisted drug dependence treatment for PWID HIV -> Prevention package for sex workers, their clients and other sexual partners -> Condom and lubricant programming for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Pre-exposure prophylaxis (PrEP) programming for sex workers HIV -> Reducing human rights-related barriers to HIV/TB services -> Eliminating stigma and discrimination in all settings HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - adults (15 and above) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - children (under 15) HIV -> Treatment, care and support -> Treatment monitoring - Viral load and antiretroviral (ARV) toxicity Multicomponent -> Program management -> Grant management RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Quality management systems and accreditation RSSH -> RSSH: Health sector planning and governance for integrated people-centered services -> Integration/coordination across disease programs and at the service delivery level RSSH -> RSSH: Monitoring and evaluation systems -> Routine reporting Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB diagnosis/drug susceptibility testing (DST) Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB treatment, care and support Tuberculosis -> TB diagnosis, treatment and care -> TB screening and diagnosis Tuberculosis -> TB/DR-TB Prevention -> Preventive treatment Tuberculosis -> TB/HIV -> TB/HIV - Key populations Tuberculosis -> TB/HIV -> TB/HIV - Screening, testing and diagnosis 5518945.54 8442683.53 9395214.06 10977476.00 Global Fund commitment to TJK-C-UNDPP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 6489759.00 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 500000.00 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3468500.00 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme -519217.00 Global Fund commitment to TJK-C-UNDPP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3700263.00 Global Fund commitment to TJK-C-UNDPP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3700263.00 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 519217.00 Global Fund commitment to TJK-C-UNDPP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 519217.00 Global Fund disbursement to TJK-C-UNDPP02 (Other 3rd Party). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2348803.53 Global Fund commitment to TJK-C-UNDPP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2348803.53 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5007156.83 Global Fund commitment to TJK-C-UNDPP02. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3200000.00 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 1059974.83 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 658057.77 Global Fund disbursement to TJK-C-UNDPP02 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5518945.54 Expenditure reported by United Nations Development Programme for TJK-C-UNDPP02, Jan 2024 to Dec 2024. United Nations Development Programme 6909925.30 Expenditure reported by United Nations Development Programme for TJK-C-UNDPP02, Jan 2025 to Dec 2025. United Nations Development Programme <narrative>Grant page on the data explorer of the Global Fund.</narrative> An overview of a grant over its lifetime. <narrative>Grant terms and conditions.</narrative> General terms and conditions which apply to Global Fund grants. <narrative>2023 - Funding Request - TB/HIV - Tajikistan - English</narrative> Funding Request of funding request FR1411-TJK-C. 1 - Personal Data. (1) Principles. Program Activities are expected to respect the following principles and rights (“Data Protection Principles”): (a) Information that could be used to identify a natural person (“Personal Data”) will be: (i) processed lawfully, fairly and transparently; (ii) collected for specified, explicit and legitimate purposes and not further processed in a manner not compatible with those purposes;  (iii) adequate, relevant and limited to what is necessary for the purposes for which they are processed; (iv) accurate and, where necessary, kept up to date; (v) kept in a form which permits identification of the individuals for no longer than is necessary for the purposes for which the Personal Data is processed; and (vi) processed in a manner that ensures appropriate security of the Personal Data; and (b) Natural persons are afforded, where relevant, the right to information about Personal Data that is processed; the right to access and rectify or erase Personal Data; the right to data portability; the right to confidentiality of electronic communications; and the right to object to processing. (2) Limitations. Where collection and processing of Personal Data is required in order to implement Program Activities, whether by the Principal Recipient, a Sub-recipient, or Supplier, the Principal Recipient should respect the Data Protection Principles: (a) to the extent that doing so does not violate or conflict with any law and/or policy applicable to it; and (b) subject to the Principal Recipient balancing the Data Protection Principles with other fundamental rights in accordance with the principle of proportionality, taking into account the risks to the rights and freedoms of natural persons. (3) The Global Fund may collect or seek to collect data, and it is possible that such data may contain Personal Data. Prior to collection and at all times thereafter, the Principal Recipient shall take all necessary actions to ensure that the transfer of such information to the Global Fund does not violate any law or regulation applicable to the Principal Recipient. 2 - In accordance with the Global Fund’s Sustainability, Transition and Co-financing Policy (GF/B35/04) (the “STC Policy”), the commitment and disbursement of USD 3,894,622, based on 15% of the country’s total Global Fund allocation, as communicated in the Allocation Letter (the “Co-Financing Incentive”), is subject to the Global Fund’s satisfaction with the Host Country’s compliance with the requirements listed at 4.2(1)(a) and 4.2(1)(b) below (“Co-Financing Requirements”). The Principal Recipient acknowledges and agrees that the Global Fund may reduce Grant Funds during the current or any subsequent Implementation Period in the event the Host Country fails to: (a) progressively increase government expenditure on health to meet national universal health coverage goals; and/or (b) increase domestic funding of Global Fund-supported programs, with a focus on progressively absorbing the key costs of national disease plans, as identified in consultation with the Global Fund. (2) In order to satisfy the Co-Financing Requirements, the Principal Recipient acknowledges and agrees that the Host Country shall, as set out in the Co-Financing Commitment Letter dated 23 August 2023 (the “Commitment Letter”), unless otherwise agreed in writing with the Global Fund: (a) fulfil a total minimum co-financing commitment of USD 43,721,963 from 2024-2026 (inclusive), comprising investments in: (i) HIV of USD 14,255,036; and (ii) TB of USD 29,466,927. (b) fulfil the programmatic commitments as stipulated in Section 1.2 of the Commitment Letter; and (c) provide to the Global Fund, by no later than 31 December of each year of the Implementation Period and the year following the end of the Implementation Period, evidence supporting the achievement of the Co-Financing Requirements, including: (i) the approved annual budget for HIV and TB for the upcoming year; and (ii) the total expenditure for HIV and TB in the previous fiscal year. For the avoidance of doubt, the Host Country’s total co-financing commitments stipulated in the Commitment Letter are higher than the total minimum co-financing commitment specified above. 3 - Under Article 3 of the UNDP-Global Fund Grant Regulations, the “Grant” consists of “funds as stated in the relevant Grant Confirmation together with any funds previously granted by the Global Fund to the Principal Recipient for the Program”. In this regard, please note that where the Global Fund has approved the use under the current Grant Confirmation of grant funds disbursed to the Principal Recipient under a previous Grant Agreement for the Program (“Previously Disbursed Grant Funds”), the Global Fund may reduce the amount of Grant Funds that remains uncommitted set forth in Section 3.6 of the Grant Confirmation by the amount of any Previously Disbursed Grant Funds, upon written notification to the Principal Recipient. 4 - To the extent consistent with and without prejudice to the Framework Agreement and, in particular, Article 2 of the UNDP-Global Fund Grant Regulations, the Principal Recipient shall be guided by the Global Fund Guidelines for Grant Budgeting (2023, as amended from time to time, available at the Global Fund’s Internet site) in the budgeting of the Grant. 5 - Unless otherwise notified by the Global Fund in writing, prior to the use of Grant Funds to finance the procurement of second-line anti-tuberculosis drugs and for each disbursement request that includes funds for the procurement of multi-drug resistant tuberculosis medicines, the Principal Recipient shall submit to the Global Fund and obtain the Global Fund’s written approval of a written confirmation of the price estimate and quantities of the second-line anti-tuberculosis drugs that will be procured by the Principal Recipient from the Global Drug Facility’s procurement agent. 6 - Prior to utilising Grant Funds to finance any research, studies and/or related activities, the Principal Recipient shall submit a written request to the Global Fund and obtain the Global Fund’s written approval of all related costed work plan, study protocol and any other relevant documentation. <narrative>Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative> Geographic coverage: National, 100% of national program target. Numerator: 10400. Numerator: 600; Denominator: 15450; Percentage: 3.88%. Numerator: 10400; Denominator: 15450; Percentage: 67.31%. Numerator: 9500. Numerator: 9600. Numerator: 242. Numerator: 9358. Numerator: 9500. Numerator: 11170. Numerator: 9500. <narrative>Percentage of MSM that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of MSM that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative> Geographic coverage: National, 100% of national program target. Numerator: 5199; Denominator: 13400. Numerator: 4443; Denominator: 12000. Numerator: 4151; Denominator: 12000. Numerator: 7773; Denominator: 12000. Numerator: 3238; Denominator: 12000. Numerator: 9180; Denominator: 12000. <narrative>Percentage of sex workers that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of sex workers that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative> Geographic coverage: National, 100% of national program target. Numerator: 8630; Denominator: 17600. Numerator: 9404; Denominator: 18500. Numerator: 7727; Denominator: 18500. Numerator: 12389; Denominator: 18500. Numerator: 8046; Denominator: 18500. Numerator: 14256; Denominator: 18500. <narrative>Number of people with confirmed RR-TB and/or MDR-TB notified</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Number of people with confirmed RR-TB and/or MDR-TB notified</narrative> Geographic coverage: National, 100% of national program target. <narrative>Percentage of RR/MDR-TB patients with DST results for Fluoroquinolone among the total number of notified RR/MDR-TB patients during the reporting period</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Percentage of RR/MDR-TB patients with DST results for Fluoroquinolone among the total number of notified RR/MDR-TB patients during the reporting period</narrative> Geographic coverage: National, 100% of national program target. Numerator: 551; Denominator: 606. Numerator: 327; Denominator: 373. Numerator: 263; Denominator: 268. <narrative>Percentage of people with confirmed RR-TB and/or MDR-TB that began second-line treatment</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Percentage of people with confirmed RR-TB and/or MDR-TB that began second-line treatment</narrative> Geographic coverage: National, 100% of national program target. Numerator: 482; Denominator: 487. Numerator: 343; Denominator: 373. Numerator: 265; Denominator: 268. <narrative>Percentage of men who have sex with men reached with HIV prevention programs</narrative> Module: Prevention package for men who have sex with men (MSM) and their sexual partners. <narrative>Percentage of men who have sex with men reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. Numerator: 7036; Denominator: 13400. Numerator: 5703; Denominator: 12000. Numerator: 4197; Denominator: 12000. Numerator: 9145; Denominator: 12000. Numerator: 5145; Denominator: 12000. Numerator: 10200; Denominator: 12000. <narrative>Number of people in prisons and other closed settings reached with HIV prevention programs</narrative> Module: Prevention package for people in prisons and other closed settings. <narrative>Number of people in prisons and other closed settings reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. <narrative>Percentage of people who inject drugs reached with HIV prevention programs</narrative> Module: Prevention package for people who use drugs (PUD) and their sexual partners. <narrative>Percentage of people who inject drugs reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. Numerator: 14644; Denominator: 22200. Numerator: 15000; Denominator: 18200. Numerator: 12402; Denominator: 18200. Numerator: 16348; Denominator: 18200. Numerator: 11837; Denominator: 18200. Numerator: 17200; Denominator: 18200. <narrative>Percentage of people who inject drugs receiving opioid substitution therapy</narrative> Module: Prevention package for people who use drugs (PUD) and their sexual partners. <narrative>Percentage of people who inject drugs receiving opioid substitution therapy</narrative> Geographic coverage: National, 100% of national program target. Numerator: 662; Denominator: 22200. Numerator: 1175; Denominator: 18200. Numerator: 598; Denominator: 18200. Numerator: 1625; Denominator: 18200. Numerator: 613; Denominator: 18200. Numerator: 2000; Denominator: 18200. <narrative>Percentage of sex workers reached with HIV prevention programs</narrative> Module: Prevention package for sex workers, their clients and other sexual partners. <narrative>Percentage of sex workers reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. Numerator: 12087; Denominator: 17600. Numerator: 11467; Denominator: 18500. Numerator: 8070; Denominator: 18500. Numerator: 14575; Denominator: 18500. Numerator: 9505; Denominator: 18500. Numerator: 15840; Denominator: 18500. <narrative>Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative> Module: TB diagnosis, treatment and care. <narrative>Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative> Geographic coverage: National, 100% of national program target. <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative> Module: TB diagnosis, treatment and care. <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative> Geographic coverage: National, 100% of national program target. Numerator: 3876; Denominator: 4441. Numerator: 3485; Denominator: 4095. <narrative>Number of people in contact with TB patients who began preventive therapy</narrative> Module: TB/DR-TB Prevention. <narrative>Number of people in contact with TB patients who began preventive therapy</narrative> Geographic coverage: National, 100% of national program target. <narrative>Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative> Module: TB/HIV. <narrative>Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative> Geographic coverage: National, 100% of national program target. Numerator: 115; Denominator: 120. Numerator: 92; Denominator: 98. Numerator: 69; Denominator: 71. <narrative>Percentage of people on ART among all people living with HIV at the end of the reporting period</narrative> Module: Treatment, care and support. <narrative>Percentage of people on ART among all people living with HIV at the end of the reporting period</narrative> Geographic coverage: National, 100% of national program target. Numerator: 9535; Denominator: 14000. Numerator: 11400; Denominator: 15000. Numerator: 11268; Denominator: 15000. Numerator: 12678; Denominator: 15000. Numerator: 12097; Denominator: 13878. Numerator: 14250; Denominator: 15000. <narrative>Percentage of pregnant women living with HIV who received antiretroviral medicine to reduce the risk of vertical transmission of HIV</narrative> Module: Treatment, care and support. <narrative>Percentage of pregnant women living with HIV who received antiretroviral medicine to reduce the risk of vertical transmission of HIV</narrative> Geographic coverage: National, 100% of national program target. Numerator: 245; Denominator: 251. Numerator: 275; Denominator: 261.